Chemotherapy for the Treatment of Adenoid Cystic Carcinoma

作者: 姜 涛 :青岛大学附属医院眼科,山东 青岛; 姜 靖 :青岛大学附属医院东区感染科,山东 青岛; 王仁萍 :青岛大学附属医院健康查体中心,山东 青岛; 肖利华 , 王 毅 :北京武警总医院眼眶病研究所,北京;

关键词: 腺样囊性癌化学治疗Adenoid Cystic Carcinoma (ACC) Chemotherapy

腺样囊性癌(adenoid cystic carcinoma, ACC)恶性程度高,其特征为缓慢地局部浸润性生长,易局部复发与远处转移,预后差,难根治,死亡率较高,于眼眶部好发于泪腺,其临床治疗一直以来就是一个难点。传统的治疗方法包括手术切除、放射治疗、化学治疗及上述方式的联合应用等综合治疗方法。大部分ACC的初发病例采用手术切除治疗,然后行放射治疗,对于复发病例,治疗选择有限,再次放疗与重复手术切除的治疗效果有限。近年来,ACC的化学治疗研究逐渐为人们所重视,本文将其研究的进展情况进行综述。

Abstract: Adenoid cystic carcinoma (ACC) is a malignant tumor, and its malignant degree is high, the cha-racteristics of which is slow local invasive growth, easy to local recurrence and distant metastasis, with poor prognosis and high mortality, difficult to cure. In orbit it occurs in the lacrimal gland. The clinical treatment has been a difficulty. Traditional treatment methods include surgery, radi-otherapy, chemotherapy, and the combination of the above methods. Most of ACC's primary cases were treated with surgical resection, followed by radiation therapy. For the treatment of recurrent cases, options are limited, and the effect of re-radiation therapy and repeat surgery is limited. In recent years, the research on the chemotherapy for ACC is gradually paid attention to. In this paper, the progress of the research is summarized.

文章引用: 姜 涛 , 姜 靖 , 王仁萍 , 肖利华 , 王 毅 (2015) 腺样囊性癌的化学治疗。 眼科学, 4, 57-68. doi: 10.12677/HJO.2015.43011


[1] Jaso, J. and Malhotra, R. (2011) Adenoid cystic carcinoma. Archives of Pathology & Laboratory Medicine, 135, 511- 515.

[2] Gondivkar, S.M., Gadbail, A.R., Chole, R. and Parikh, R.V. (2011) Adenoid cystic carcinoma: A rare clinical entity and literature review. Oral Oncology, 47, 231-236.

[3] Sasahira, T., Kurihara, M., Yamamoto, K., Bhawal, U.K., Kirita, T. and Kuniyasu, H. (2011) Downregulation of runt- related transcription factor 3 associated with poor prognosis of adenoid cystic and mucoepidermoid carcinomas of the salivary gland. Cancer Science, 102, 492-497.

[4] Vacchi-Suzzi, M., Bocciolini, C., Bertarelli, C. and Dall’Olio, D. (2010) Ki-67 proliferation rate as a prognostic marker in major salivary gland carcinomas. Annals of Otology, Rhinology & Laryngology, 119, 677-683.

[5] Bell, D., Roberts, D., Kies, M., Rao, P., Weber, R.S. and El-Naggar, A.K. (2010) Cell type-dependent biomarker expression in adenoid cystic carcinoma: Biologic and therapeutic implications. Cancer, 116, 5749-5756.

[6] Tetsu, O., Phuchareon, J., Chou, A., Cox, D.P., Eisele, D.W. and Jordan, R.C. (2010) Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands. Neoplasia, 12, 708-717.

[7] Boukheris, H., Curtis, R.E., Land, C.E. and Dores, G.M. (2009) Inci-dence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: A population-based study in the United States. Cancer Epidemiology, Biomarkers & Prevention, 18, 2899-2906.

[8] Saito, M., Nishiyama, H., Maruyama, S., Oda, Y., Saku, T. and Hayashi, T. (2008) Adenoid cystic carcinoma of sublingual gland involving the submandibular duct. Dentomax-illofacial Radiology, 37, 421-424.

[9] Birkeland, S. (2003) Spinal metastasis of submandibular gland adenoid cystic carcinoma: A case report. Surgical Neurology, 60, 265-266.

[10] Al-Khateeb, T.H. and Ababneh, K.T. (2007) Salivary tumors in north Jordanians: A descriptive study. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 103, e53-e59.

[11] de Oliveira, F.A., Duarte, E.C., Taveira, C.T., Máximo, A.A., de Aquino, E.C., Alencar Rde, C. and Vencio, E.F. (2009) Salivary gland tumor: A review of 599 cases in a Brazilian population. Head and Neck Pathology, 3, 271-275.

[12] Fujii, Y., Masuda, M., Hirokawa, M., Matsushita, K. and Ha-segawa, H. (1991) Bilateral renal metastases of lung adenoid cystic carcinoma. Hinyokika Kiyo, 37, 1307-1311.

[13] Campistron, M., Rouquette, I., Courbon, F., Chabbert, V., Rochaix, P., Prévot, G., Laroumagne, S., Têtu, L., Didier, A. and Mazières, J. (2008) Adenoid cystic carcinoma of the lung: interest of 18FDG PET/CT in the management of an atypical presentation. Lung Cancer, 59, 133-136.

[14] Yurut-Caloglu, V., Caloglu, M., Ozyilmaz, F., Saynak, M., Cosar-Alas, R., Karagol, H., Bayir-Angin, G. and Uzal, C. (2007) Lung, bone, skeletal muscles and cutaneous metastases from adenoid cystic carcinoma of the parotid gland: A case report and review of the literature. Medical Oncology, 24, 458-462.

[15] Yokouchi, H., Otsuka, Y., Otoguro, Y., Takemoto, N., Ito, K., Uchida, Y., Okamoto, K., Nishimura, M., Kimura, K. and Kaji, H. (2007) Primary peripheral adenoid cystic carcinoma of the lung and literature comparison of features. Internal Medicine, 46, 1799-1803.

[16] Aubry, M.C., Heinrich, M.C., Molina, J., Lewis, J.E., Yang, P., Cassivi, S.D. and Corless, C.L. (2007) Primary adenoid cystic carcinoma of the lung: Absence of KIT muta-tions. Cancer, 110, 2507-2510.

[17] Park, I., Lim, S.N., Yoon, D.H., Park, H., Sun, B., Lee, P.H., Hwang, I. and Lee, D.H. (2009) Metastasectomy for hepatic metastases from adenoid cystic carcinoma of the trachea. Gut and Liver, 3, 127-129.

[18] Haresh, K.P., Prabhakar, R., Rath, G.K., Sharma, D.N., Julka, P.K. and Subramani, V. (2008) Adenoid cystic carcinoma of the trachea treated with PET-CT based intensity modulated radiotherapy. Journal of Thoracic Oncology, 3, 793- 795.

[19] Law, Y.M., Quek, S.T., Tan, P.H. and Wong, S.L. (2009) Adenoid cystic carcinoma of the breast. Singapore Medical Journal, 50, e8-e11.

[20] Kshirsagar, A.Y., Wader, J.V., Langade, Y.B., Jadhav, K.P., Zaware, S.U. and Shekhar, N. (2006) Adenoid cystic carcinoma of the male breast. In-ternational Surgery, 91, 234-236.

[21] Dores, G.M., Huycke, M.M., Devesa, S.S. and Garcia, C.A. (2010) Primary cutaneous adenoid cystic carcinoma in the United States: Incidence, survival, and associated cancers, 1976 to 2005. Journal of the American Academy of Dermatology, 63, 71-78.

[22] Benchetritt, M., Butori, C., Long, E., Ilie, M., Ferrari, E. and Hofman, P. (2008) Pericardial effusion as primary manifestation of metastatic cutaneous adenoid cystic carcinoma: di-agnostic cytopathology from an exfoliative sample. Diagnostic Cytopathology, 36, 351-354.

[23] Meel, R., Pushker, N. and Bakhshi, S. (2009) Adjuvant chemotherapy in lacrimal gland adenoid cystic carcinoma. Pediatric Blood & Cancer, 53, 1163-1164.

[24] Tse, D.T., Benedetto, P., Dubovy, S., Schiffman, J.C. and Feuer, W.J. (2006) Clinical analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. American Journal of Ophthalmology, 141, 44-53.

[25] Esmaeli, B., Golio, D., Kies, M. and DeMonte, F. (2006) Surgical management of locally advanced adenoid cystic carcinoma of the lacrimal gland. Ophthalmic Plastic & Reconstructive Surgery, 22, 366-370.

[26] Tse, D.T., Finkelstein, S.D., Benedetto, P., Dubovy, S., Schiffman, J. and Feuer, W.J. (2006) Microdissection genotyping analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. American Journal of Ophthalmology, 141, 54-61.

[27] Friedrich, R.E. and Bleckmann, V. (2003) Adenoid cystic carcinoma of salivary and lacrimal gland origin: Localization, classification, clinical pathological correlation, treatment results and long-term follow-up control in 84 patients. Anticancer Research, 23, 931-940.

[28] Ducrey, N., Villemure, J.G. and Jaques, B. (2002) Cystic adenocarcinomas of the lacrymal gland. Klinische Monatsblätter für Augenheilkunde, 219, 231-234.

[29] Tellado, M.V., McLean, I.W., Specht, C.S. and Varga, J. (1997) Adenoid cystic carcinomas of the lacrimal gland in childhood and adolescence. Ophthalmology, 104, 1622-1625.

[30] Marsh, J.L., Wise, D.M., Smith, M. and Schwartz, H. (1981) Lacrimal gland adenoid cystic carcinoma: Intracranial and extracranial en bloc resection. Plastic and Reconstructive Surgery, 68, 577-585.

[31] Lloyd, S., Yu, J.B., Wilson, L.D. and Decker, R.H. (2011) Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy. American Journal of Clinical Oncology, 34, 76-81.

[32] Garden, A.S., Weber, R.S., Morrison, W.H., Ang, K.K. and Peters, L.J. (1995) The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. International Journal of Radiation Oncology*Biology*Physics, 32, 619-626.

[33] Rapidis, A.D., Givalos, N., Gakiopoulou, H., Faratzis, G., Stavrianos, S.D., Vilos, G.A., Douzinas, E.E. and Patsouris, E. (2005) Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature. Oral Oncology, 41, 328-335.

[34] Alberico, R.A., Husain, S.H. and Sirotkin, I. (2004) Imaging in head and neck oncology. Surgical Oncology Clinics of North America, 13, 13-35.

[35] Sousa, J., Sharma, R.R., Delmendo, A. and Pawar, S.J. (2001) Primary orbito-cranial adenoid cystic carcinoma with torcular metastasis: A case report and review of the literature. Journal of Clinical Neuroscience, 8, 173-176.

[36] Buchholz, T.A., Shimotakahara, S.G., Weymuller Jr., E.A., Lara-more, G.E. and Griffin, T.W. (1993) Neutron radiotherapy for adenoid cystic carcinoma of the head and neck. Archives of Otolaryngology—Head and Neck Surgery, 119, 747-752.

[37] Bobbio, A., Copelli, C., Ampollini, L., Bianchi, B., Carbognani, P., Bettati, S., Sesenna, E. and Rusca, M. (2008) Lung metastasis resection of adenoid cystic carcinoma of salivary glands. European Journal of Cardio-Thoracic Surgery, 33, 790-793.

[38] Spiro, R.H. (1997) Distant metastasis in adenoid cystic carci-noma of salivary origin. The American Journal of Surgery, 174, 495-498.

[39] Sung, M.W., Kim, K.H., Kim, J.W., Min, Y.G., Seong, W.J., Roh, J.L., Lee, S.J., Kwon, T.K. and Park, S.W. (2003) Clinicopathologic predictors and impact of distant me-tastasis from adenoid cystic carcinoma of the head and neck. Archives of Otolaryngology—Head and Neck Surgery, 129, 1193-1197.

[40] Font, R.L., Smith, S.L. and Bryan, R.G. (1998) Malignant epithelial tumors of the lacrimal gland: A clinicopathologic study of 21 cases. Archives of Ophthalmology, 116, 613-616.

[41] Szanto, P.A., Luna, M.A., Tortoledo, M.E. and White, R.A. (1984) Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer, 54, 1062-1069.

[42] Bradley, P.J. (2004) Adenoid cystic carcinoma of the head and neck: A review. Current Opinion in Otolaryngology & Head and Neck Surgery, 12, 127-132.

[43] Gupta, A.K., Wilke, W.W., Taylor, E.N., Bodeker, K.L., Hoffman, H.T., Milhem, M.M., Buatti, J.M. and Robinson, R.A. (2009) Signaling pathways in adenoid cystic cancers: Implications for treatment. Cancer Biology & Therapy, 8, 1947-1951.

[44] Laurie, S.A. and Licitra, L. (2006) Systemic therapy in the palliative management of advanced salivary gland cancers. Journal of Clinical Oncology, 24, 2673-2678.

[45] Laurie, S.A., Siu, L.L., Winquist, E., Maksymiuk, A., Harnett, E.L., Walsh, W., Tu, D. and Parulekar, W.R. (2010) A phase 2 study of platinum and gemcitabine in patients with ad-vanced salivary gland cancer: A trial of the NCIC clinical trials group. Cancer, 116, 362-368.

[46] Dreyfuss, A.I., Clark, J.R., Fallon, B.G., Posner, M.R., Norris Jr., C.M. and Miller, D. (1987) Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer, 60, 2869-2872.

[47] Airoldi, M., Pedani, F., Brando, V., Gabriele, P. and Giordano, C. (1989) Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Tumori Journal, 75, 252-256.

[48] Triozzi, P.L., Brantley, A., Fisher, S., Cole, T.B., Crocker, I. and Huang, A.T. (1987) 5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck. Cancer, 59, 887-890.

[49] De Dosso, S., Mazzucchelli, L., Ghielmini, M. and Saletti, P. (2009) Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma. Tumori Journal, 95, 378-381.

[50] Meldrum, M.L., Tse, D.T. and Benedetto, P. (1998) Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland. Archives of Ophthalmology, 116, 315-321.

[51] Goldberg, R.A. (1998) Intra-arterial chemotherapy: A welcome new idea for the management of adenocystic carcinoma of the lacrimal gland. Archives of Ophthalmology, 116, 372-373.

[52] Tse, D.T. (2005) Clinical and microdissection genotyping analyses of the effect of intra-arterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. Transactions of the American Ophthalmological Society, 103, 337-367.

[53] Maruya, S., Namba, A., Matsubara, A., Kakehata, S., Takeda, I., Shirasaki, T., Hatayama, Y., Nagahata, M., Yokoyama, J. and Shinkawa, H. (2006) Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel. International Journal of Clinical Oncology, 11, 403-406.

[54] Bernardini, F.P., Devoto, M.H. and Croxatto, J.O. (2008) Epi-thelial tumors of the lacrimal gland: An update. Current Opinion in Ophthalmology, 19, 409-413.

[55] 金有豫 (2002) 药理学. 人民卫生出版社, 北京, 389-390.

[56] Durdux, C. (2004) Cisplatin and derivatives with radiation therapy: For what clinical use? Cancer Ra-diothérapie, 8, S88-S94.

[57] Ahmed, A.R. and Hombal, S.M. (1984) Cyclophosphamide (Cytoxan). A review on re-levant pharmacology and clinical uses. Journal of the American Academy of Dermatology, 11, 1115-1126.

[58] Van Triest, B., Pinedo, H.M., Giaccone, G. and Peters, G.J. (2000) Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Annals of Oncology, 11, 385-391.

[59] Peters, G.J., Backus, H.H., Freemantle, S., van Triest, B., Co-dacci-Pisanelli, G., van der Wilt, C.L., Smid, K., Lunec, J., Calvert, A.H., Marsh, S., McLeod, H.L., Bloemena, E., Meijer, S., Jansen, G., van Groeningen, C.J. and Pinedo, H.M. (2002) Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochimica et Biophysica Acta, 1587, 194-205.

[60] Bunz, F. (2008) Thymidylate synthase and 5-fluorouracil: a cautionary tale. Cancer Biology & Therapy, 7, 995-996.

[61] Showalter, S.L., Showalter, T.N., Witkiewicz, A., Havens, R., Kennedy, E.P., Hucl, T., Kern, S.E., Yeo, C.J. and Brody, J.R. (2008) Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biology & Therapy, 7, 986-994.

[62] Nelson, R.L. (1982) The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. Medical and Pediatric On-cology, 10, 115-127.

[63] Cersosimo, R.J. and Hong, W.K. (1986) Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. Journal of Clinical Oncology, 4, 425-439.

[64] Mini, E., Nobili, S., Caciagli, B., Landini, I. and Mazzei, T. (2006) Cellular pharmacology of gemcitabine. Annals of Oncology, 17, v7-v12.

[65] Wong, A., Soo, R.A., Yong, W.P. and Innocenti, F. (2009) Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metabolism Reviews, 41, 77-88.

[66] van Herpen, C.M., Locati, L.D., Buter, J., Thomas, J., Bogaerts, J., Lacombe, D., de Mulder, P., Awada, A., Licitra, L., Bernier, J. and Vermorken, J.B. (2008) Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). European Journal of Cancer, 44, 2542-2545.

[67] Trudeau, M.E. (1996) Docetaxel: A review of its pharmacology and clinical activity. Canadian Journal of Oncology, 6, 443-457.

[68] Alimoghaddam, K., Ghavamzadeh, A., Jahani, M., Mousavi, A., Iravani, M., Rostami, S., Ghaffari, H., Hosseini, R. and Jalili, M. (2011) Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran. Archive of Iranian Medicine, 14, 167-169.

[69] Baĭdil'dina, D.D., Maschan, M.A., Skorobogatova, E.V., Dubrovina, M.E., Rumiantseva, I.V., Maschan, A.A., Rumiantsev, A.G. and Samochatova, E.V. (2010) Recurrences of acute promyelocytic leukemia in children: Experience with arsenic trioxide therapy and autologous hematopoietic cell transplantation. Terapevticheskiĭ Arkhiv, 82, 20-25.

[70] Powell, B.L., Moser, B., Stock, W., Gallagher, R.E., Willman, C.L., Stone, R.M., Rowe, J.M., Coutre, S., Feusner, J.H., Gregory, J., Couban, S., Appelbaum, F.R., Tallman, M.S. and Larson, R.A. (2010) Arsenic trioxide improves event- free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood, 116, 3751-3757.

[71] Mathews, V., George, B., Chendamarai, E., Lakshmi, K.M., Desire, S., Balasubramanian, P., Viswabandya, A., Thirugnanam, R., Abraham, A., Shaji, R.V., Srivastava, A. and Chandy, M. (2010) Single-agent arsenic trioxide in the treatment of newly diagnosed acute pro-myelocytic leukemia: Long-term follow-up data. Journal of Clinical Oncology, 28, 3866-3871.

[72] Mandegary, A., Hosseini, R., Ghaffari, S.H., Alimoghaddam, K., Rostami, S., Ghavamzadeh, A. and Ghahremani, M.H. (2010) The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide. Annals of On-cology, 21, 1884-1890.

[73] Cui, X., Wakai, T., Shirai, Y., Yokoyama, N., Hatakeyama, K. and Hirano, S. (2006) Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. Human Pathology, 37, 298-311.

[74] Park, J.H., Kim, E.J., Jang, H.Y., Shim, H., Lee, K.K., Jo, H.J., Kim, H.J., Yang, S.H., Jeong, E.T. and Kim, H.R. (2008) Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncology Reports, 20, 379-384.

[75] Wang, W., Adachi, M., Zhang, R., Zhou, J. and Zhu, D. (2009) A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells. Pancreas, 38, e114-e123.

[76] Stevens, J.J., Graham, B., Walker, A.M., Tchounwou, P.B. and Rogers, C. (2010) The effects of arsenic trioxide on DNA synthesis and genotoxicity in human colon cancer cells. International Journal of Environmental Research and Public Health, 7, 2018-2032.

[77] Chow, S.K., Chan, J.Y. and Fung, K.P. (2004) Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. Journal of Cellular Biochemistry, 93, 173-187.

[78] Wang, X., Ren, J.H., Lin, F., Wei, J.X., Long, M., Yan, L. and Zhang, H.Z. (2010) Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway. Cancer Biology & Therapy, 10, 632-643.

[79] Li, H.M., Long, Y., Qing, C., Yu, M., Li, Z.H., Zhang, X.M., Li, X.J., Chen, Y.J., Zhang, Y.L. and Liang, Y. (2011) Arsenic trioxide induces apoptosis of Burkitt lymphoma cell lines through multiple apoptotic pathways and triggers anti-angiogenesis. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 19, 149-163.

[80] Kchour, G., Tarhini, M., Kooshyar, M.M., El Hajj, H., Wattel, E., Mahmoudi, M., Hatoum, H., Rahimi, H., Maleki, M., Rafatpanah, H., Rezaee, S.A., Yazdi, M.T., Shirdel, A., de Thé, H., Hermine, O., Farid, R. and Bazarbachi, A. (2009) Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leuke-mia/lymphoma (ATL). Blood, 113, 6528-6532.

[81] Hu, T., Shi, J., Jiao, X., Zhou, J. and Yin, X. (2008) Mea-surement of annexin V uptake and lactadherin labeling for the quantification of apoptosis in adherent Tca8113 and ACC-2 cells. Brazilian Journal of Medical and Biological Research, 41, 750-757.